Madrigal Pharmaceuticals (MDGL) EBIAT (2019 - 2025)
Madrigal Pharmaceuticals (MDGL) has disclosed EBIAT for 13 consecutive years, with -$58.6 million as the latest value for Q4 2025.
- Quarterly EBIAT rose 1.37% to -$58.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$288.3 million through Dec 2025, up 38.12% year-over-year, with the annual reading at -$288.3 million for FY2025, 38.12% up from the prior year.
- EBIAT for Q4 2025 was -$58.6 million at Madrigal Pharmaceuticals, up from -$114.2 million in the prior quarter.
- The five-year high for EBIAT was -$42.3 million in Q2 2025, with the low at -$152.0 million in Q2 2024.
- Average EBIAT over 5 years is -$83.3 million, with a median of -$75.1 million recorded in 2023.
- The sharpest move saw EBIAT plummeted 91.87% in 2024, then skyrocketed 72.18% in 2025.
- Over 5 years, EBIAT stood at -$64.5 million in 2021, then plummeted by 33.08% to -$85.9 million in 2022, then plummeted by 30.6% to -$112.2 million in 2023, then skyrocketed by 47.04% to -$59.4 million in 2024, then rose by 1.37% to -$58.6 million in 2025.
- According to Business Quant data, EBIAT over the past three periods came in at -$58.6 million, -$114.2 million, and -$42.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.